Fermenta Biotech News

Fermenta Biotech News 2026

Fermenta Biotech Stock

Fermenta Biotech Fermenta Biotech Ltd manufactures and supplies Vitamin D3, operating through its Chemicals/Bulk Drug segment that produces bulk drugs and enzymes for pharmaceuticals, dietary supplements, food fortification, animal feed, veterinary, and rodenticide industries. The Property segment generates revenue by renting and selling properties. The company's proprietary enzyme portfolio supports biopharmaceutical product development, while its nutritional ingredients include fish oil-derived cholesterol for aquaculture, natural astaxanthin, and vitamin AD2 premix, all sold to customers in the specified sectors. The Chemicals/Bulk Drug segment serves pharmaceutical, dietary supplement, food and beverage, animal feed, veterinary, and rodenticide markets with bulk drugs and enzymes. The Property segment focuses on real estate transactions, providing rental and sales services for its properties. Fermenta Biotech's product portfolio targets industries requiring specialized biopharmaceutical technologies and nutritional supplements, with key offerings like Vitamin D3, fish oil cholesterol, astaxanthin, and vitamin AD2 premix directly sold to these sectors. Fermenta Biotech Ltd's revenue streams come from the sale of Vitamin D3 and other bulk drugs through its Chemicals/Bulk Drug segment, while the Property segment contributes through property rentals and sales. The company's nutritional ingredients, such as fish oil-derived cholesterol, natural astaxanthin, and vitamin AD2 premix, are sold to industries including pharmaceuticals, dietary supplements, food fortification, animal feed, and veterinary sectors, with no additional brand or customer details provided beyond the business description.